Humacyte Inc (HUMA : NASDAQ)
Common Stock
Follow HUMA
HUMA
Humacyte Inc
WealthAwesomePerformance
1 Day
+29.61%
1 Week
+33.94%
1 Month
+45.68%
YTD
-39.11%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$126.45M
52W High
$1.52
52W Low
$0.34
P/E Ratio
-
50 Day MA
$0.50
200 Day MA
$0.79
Beta
2.68
Dividend Yield
-
Performance history
HUMA returns since 2026
Humacyte Inc has traded since Jun 2026 in our data. Its deepest fall was −63.5% (Jun 2026 to Oct 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2026*−39.1%
* Partial year (first year of data, or year to date).
$10,000 invested in HUMA
- 2026 (start of our data)$6,089
- All-time high in our data
- $1 on Jun 17, 2026 · now −39.1%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Jun 2026 to Nov 2026. Past returns do not predict future ones.
Awesome Portfolio™
Looking past HUMA? Our 10 best Canadian stocks, in one list.
14.8% a year since 2017 against 9.7% for the S&P/TSX Composite (+5.0 points a year). Reviewed every month.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/10/2026 | $0.50 | $0.60 | $0.49 | $0.59 | $0.59 | 15,525,812 |
| 11/9/2026 | $0.45 | $0.49 | $0.45 | $0.46 | $0.46 | 5,570,446 |
| 11/6/2026 | $0.41 | $0.45 | $0.40 | $0.45 | $0.45 | 5,152,000 |
| 11/5/2026 | $0.44 | $0.45 | $0.39 | $0.40 | $0.40 | 5,954,928 |
| 11/4/2026 | $0.46 | $0.47 | $0.42 | $0.45 | $0.45 | 2,641,900 |
| 11/3/2026 | $0.40 | $0.45 | $0.39 | $0.44 | $0.44 | 3,168,893 |
| 11/2/2026 | $0.42 | $0.43 | $0.39 | $0.40 | $0.40 | 5,214,436 |
| 10/30/2026 | $0.46 | $0.46 | $0.40 | $0.41 | $0.41 | 5,070,900 |
| 10/29/2026 | $0.47 | $0.51 | $0.46 | $0.47 | $0.47 | 3,704,476 |
| 10/28/2026 | $0.45 | $0.48 | $0.43 | $0.47 | $0.47 | 2,636,176 |
Analyst Price Targets
Based on 6 analysts covering HUMA · as of Oct 26, 2026
Wall Street analysts forecast HUMA stock price to rise 175.4% over the next 12 months.
Consensus
Buy4.17 / 5.00
Avg. Target
US$1.63
+175.4% Upside
Current Price
US$0.59
Last close
Analyst Breakdown (6 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HUMA's historical volatility
30-Day Vol
142.4%
Annualized
90-Day Vol
109.1%
Annualized
Trend (90d)
+21.2%
Annualized drift
90d Mean
US$0.64
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.61 | US$0.37 – US$0.99 |
| 60 trading days | US$0.62 | US$0.31 – US$1.24 |
| 90 trading days | US$0.64 | US$0.27 – US$1.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Financials
- Revenue (TTM)
- $2.12M
- EBITDA
- $-103.23M
- Profit Margin
- 0.00%
- ROE (TTM)
- -547.87%
- EPS (Diluted)
- -0.51
- Book Value
- 0.11
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About HUMA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| SMX | SMX (Security Matters) Public Limited Company Class A Ordinary Shares | $19.25 | +105.88% |
| PEPG | PepGen Ltd | $4.61 | +92.89% |
| TTEC | TTEC Holdings Inc | $2.40 | +72.04% |
| NNOX | Nano X Imaging Ltd | $0.37 | +59.80% |
| TANH | Tantech Holdings Ltd | $30.56 | +58.01% |
| AACG | ATA Creativity Global | $0.89 | +52.14% |
| ESLA | Estrella Immunopharma Inc. | $0.75 | +45.40% |
| MNDO | MIND CTI Ltd | $1.26 | +44.83% |
Free with a Wealth Awesome account
Keep analysing HUMA, free
- Every WA Score, ranking and table
- Insider track records and SEDI filings
- Earnings history and analyst targets for every stock
Email only, no password, no card. Already a member? Use the same button to sign in.